All Photos(1)

Key Documents

COO/COA

View All Documentation

E-067

Ethosuximide solution

Name: Ethosuximide solution
Brand: CERILLIAN

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₇H₁₁NO₂

CAS Number:

77-67-8

Molecular Weight:

141.17

EC Number:

200-659-6

UNSPSC Code:

41116107

grade

certified reference material

Quality Level

300

feature

Snap-N-Spike^®/Snap-N-Shoot^®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant^®

concentration

1.0 mg/mL in methanol

format

single component solution

storage temp.

−20°C

SMILES string

CCC1(C)CC(=O)NC1=O

InChI

1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)

InChI key

HAPOVYFOVVWLRS-UHFFFAOYSA-N

Gene Information

human ... CACNA1G(8913) , CACNA1H(8912) , CACNA1I(8911)

General description

Ethosuximide is an anticonvulsant specifically used to treat absence seizures. This Snap-N-Spike^® Reference Solution is suitable for LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.

Description

Pricing

Signal Word

Danger

Hazard Statements

H225,H301 + H311 + H331,H370

Precautionary Statements

P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

EU REACH Annex XVII (Restriction List)

CAS No.

67-56-1

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Design and characterization of a novel amphiphilic chitosan nanocapsule-based thermo-gelling biogel with sustained in vivo release of the hydrophilic anti-epilepsy drug ethosuximide.

Meng-Hsuan Hsiao et al.

Journal of controlled release : official journal of the Controlled Release Society, 161(3), 942-948 (2012-06-02)

Thermo-gelling injectable nanogels, with no burst release of loaded drug, were prepared by a simple route by combining self assembled nanocapsules of amphiphilically modified chitosan with glycerophosphate di-sodium salt and glycerol. The potential as a depot drug delivery system was

[Does antiabsence drug ethosuximide exert antidepressant effect?].

K Iu Sarkisova et al.

Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 61(2), 227-235 (2011-06-17)

Antiabsence drug ethosuximide (300 mg/kg/day in drinking water for 17 days) produced an antidepressant effect (a decrease in immobility time in forced swimming test) only in WAG/Rij rats genetically predisposed to absence epilepsy only at age of 5 months when

Ethosuximide reduces allodynia and hyperalgesia and potentiates morphine effects in the chronic constriction injury model of neuropathic pain.

Gholam Ali Hamidi et al.

European journal of pharmacology, 674(2-3), 260-264 (2011-12-03)

Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system and treatment of neuropathic pain remains a challenge. The purpose of the present study was to examine the effect of ethosuximide, an anti-epileptic and relatively selective

Non-convulsive status epilepticus of frontal origin in mucopolysaccharidosis type II successfully treated with ethosuximide.

Paolo Bonanni et al.

Developmental medicine and child neurology, 54(10), 961-964 (2012-03-15)

At 7 years of age, a female with mucopolysaccharidosis type II (MPS II) showed a sudden deterioration in neurological function, a sleep disorder, and progressive behavioural impairment. Electroencephalography was performed 1 year and 8 months after the onset of the

Benign myoclonic epilepsy in infancy with preceding afebrile generalized tonic-clonic seizures in Japan.

Susumu Ito et al.

Brain & development, 34(10), 829-833 (2012-03-06)

Benign myoclonic epilepsy in infancy (BMEI) is the youngest form of idiopathic generalized epilepsy, characterized by myoclonic seizures (MS) in the first three years of life in otherwise normal infants, and the lack of other seizure types except for rare

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service